Endocrine pancreatic tumors: factors correlated with survival

被引:176
作者
Tomassetti, P
Campana, D
Piscitelli, L
Casadei, R
Santini, D
Nori, F
Morselli-Labate, AM
Pezzilli, R
Corinaldesi, R
机构
[1] Univ Bologna, Dept Internal Med & Gastroenterol, Policlin S Orsola, I-40138 Bologna, Italy
[2] Univ Bologna, Dipartimento Clin Sci Chirurg & Anestesiol, I-40138 Bologna, Italy
[3] Univ Bologna, Dept Clin Sci Radiol & Istopatol, I-40138 Bologna, Italy
关键词
endocrine pancreatic tumor; gastrinoma; multiple endocrine neoplasia; octreotide; surgical procedure;
D O I
10.1093/annonc/mdi358
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to evaluate the survival rate of patients with endocrine tumors of the pancreas, functioning or non-functioning, associated or not with MEN 1 syndrome. Patients and methods: Eighty-three patients with pancreatic endocrine tumors diagnosed in our department from 1978 to 2003 were studied. Results: The study included 37 men (44.6%) and 46 women (55.4%). The median age of patients at diagnosis was 55 years (range 19-81 years). Fifty-two patients (62.7%) had non-functioning endocrine tumors, 16 (19.3%) had functioning endocrine tumors and 15 (18.1%) had MEN 1 disease with pancreatic involvement. Twenty-seven patients (32.5%) had liver metastases at the time of diagnosis, involvement of the lymph nodes was found in 47 out of 79 patients (59.5%). Forty patients (48.2%) had radical surgery, 20 (24.1%) had palliative surgery and 53 were treated medically. The survival rate was significantly related to the presence of metastases, lymph node involvement, and the type of tumor and treatment. Conclusions: Tumor resection, the absence of liver and lymph node metastases, and the presence of MEN 1 syndrome are related to a better survival rate. Radical surgery continues to have a central role in the therapeutic approach to endocrine tumors of the pancreas.
引用
收藏
页码:1806 / 1810
页数:5
相关论文
共 33 条
  • [1] Hereditary pancreatic endocrine tumours
    Alexakis, N
    Connor, S
    Ghaneh, P
    Lombard, M
    Smart, HL
    Evans, J
    Hughes, M
    Garvey, CJ
    Vora, J
    Vinjamuri, S
    Sutton, R
    Neoptolemos, JP
    [J]. PANCREATOLOGY, 2004, 4 (05) : 417 - 433
  • [2] [Anonymous], CANC PRINCIPLES PRAC
  • [3] Neuroendocrine tumours
    Barakat, MT
    Meeran, K
    Bloom, SR
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (01) : 1 - 18
  • [4] PANCREATIC-ISLET CELL-CARCINOMA .1. CLINICAL FEATURES OF 52 PATIENTS
    BRODER, LE
    CARTER, SK
    [J]. ANNALS OF INTERNAL MEDICINE, 1973, 79 (01) : 101 - 107
  • [5] BROUGHAN TA, 1986, SURGERY, V99, P671
  • [6] Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas
    Chu, QD
    Hill, HC
    Douglass, HO
    Driscoll, D
    Smith, JL
    Nava, HR
    Gibbs, JF
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2002, 9 (09) : 855 - 862
  • [7] Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?
    Corleto, VD
    Annibale, B
    Gibril, F
    Angeletti, S
    Serrano, J
    Venzon, DJ
    Delle Fave, G
    Jensen, RT
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (10) : 1555 - 1561
  • [8] Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas
    de Herder, WW
    Krenning, EP
    van Eijck, CHJ
    Lamberts, SWJ
    [J]. ENDOCRINE-RELATED CANCER, 2004, 11 (01) : 19 - 34
  • [9] Multiple endocrine neoplasia type 1
    Doherty, GM
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2005, 89 (03) : 143 - 150
  • [10] Neuroendocrine tumours of the pancreas
    Eriksson, B
    Öberg, K
    [J]. BRITISH JOURNAL OF SURGERY, 2000, 87 (02) : 129 - 131